The company said that net proceeds from the round are currently slated to support further commercialization of its coronary robotic-assisted intervention programs as well as expanding the capabilities of its CorPath system, according to an SEC filing.
The Waltham, Mass.-based company has not yet released any more details about the offering.
Last month, Corindus Vascular Robotics announced the closing of a $45 million offering and 4th quarter and fiscal year 2016 earnings which just missed expectations on Wall Street.
In the offering, Corindus floated an aggregate of 68.1 million shares of common stock at 66¢ per share, with proceeds intended to support general corporate purposes as well as commercialization of its next-gen CorPath GRX system.
As part of the funding round, Dr. Louis Cannon of the Cardiac & Vascular Research Center of Northern Michigan was appointed to the company’s board of directors.